INTRODUCTION: Opsoclonus-myoclonus syndrome (OMS) is an autoimmune paraneoplastic disorder characterized by B and T cell abnormalities in cerebrospinal fluid (CSF) and propensity for relapse. The study aim was to assess whether rituximab-induced B cell ablation in CSF outlasts repopulation in blood and if there are changes in other lymphocyte subsets. MATERIALS AND METHODS: In 25 children with OMS, the expression of CSF and blood lymphocyte surface antigens was evaluated by flow cytometry before and at intervals after rituximab therapy. RESULTS: The reduction in CSF CD27+ memory, CD38+ activated, CD5+, and other B cell subsets was profound (p < 0.0001), comparable across groups (-94%), and sustained over 12-18 months despite repopulation in blood. The observed lag in memory B cell pool recovery in the CSF compared to peripheral blood may be clinically relevant. T cell phenotypic changes involved frequency, not absolute counts, and were transient. Co-treatment with IVIg or ACTH did not significantly alter B cell depletion or repletion. DISCUSSION: These data indicate that rituximab affords long-term protection against CSF B cell expansion in OMS (ClinicalTrials.gov NCT00244361).
INTRODUCTION:Opsoclonus-myoclonus syndrome (OMS) is an autoimmune paraneoplastic disorder characterized by B and T cell abnormalities in cerebrospinal fluid (CSF) and propensity for relapse. The study aim was to assess whether rituximab-induced B cell ablation in CSF outlasts repopulation in blood and if there are changes in other lymphocyte subsets. MATERIALS AND METHODS: In 25 children with OMS, the expression of CSF and blood lymphocyte surface antigens was evaluated by flow cytometry before and at intervals after rituximab therapy. RESULTS: The reduction in CSF CD27+ memory, CD38+ activated, CD5+, and other B cell subsets was profound (p < 0.0001), comparable across groups (-94%), and sustained over 12-18 months despite repopulation in blood. The observed lag in memory B cell pool recovery in the CSF compared to peripheral blood may be clinically relevant. T cell phenotypic changes involved frequency, not absolute counts, and were transient. Co-treatment with IVIg or ACTH did not significantly alter B cell depletion or repletion. DISCUSSION: These data indicate that rituximab affords long-term protection against CSF B cell expansion in OMS (ClinicalTrials.gov NCT00244361).
Authors: Elizabeth D Tate; Tyler J Allison; Michael R Pranzatelli; Steven J Verhulst Journal: J Pediatr Oncol Nurs Date: 2005 Jan-Feb Impact factor: 1.636
Authors: R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz Journal: Arthritis Rheum Date: 2004-08
Authors: Michael R Pranzatelli; Anna L Travelstead; Elizabeth D Tate; Tyler J Allison; Steven J Verhulst Journal: Mov Disord Date: 2004-07 Impact factor: 10.338
Authors: Avinash Agarwal; Carlos A Vieira; Benita K Book; Richard A Sidner; N S Fineberg; Mark D Pescovitz Journal: Am J Transplant Date: 2004-08 Impact factor: 8.086
Authors: Christopher T Harp; Sara Ireland; Laurie S Davis; Gina Remington; Bonnie Cassidy; Petra D Cravens; Olaf Stuve; Amy E Lovett-Racke; Todd N Eagar; Benjamin M Greenberg; Michael K Racke; Lindsay G Cowell; Nitin J Karandikar; Elliot M Frohman; Nancy L Monson Journal: Eur J Immunol Date: 2010-10 Impact factor: 5.532
Authors: Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle Journal: CNS Drugs Date: 2012-01-01 Impact factor: 5.749